Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
Blood · 15.05.2025 · 145 (20) · 2312-2316
DOI: 10.1182/blood.2024028005 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Blood, erschienen am 15.05.2025. Verfasst von Zachariah DeFilipp und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Graft vs Host Disease, Pyrazoles, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Despite recent advances in graft-versus-host disease (GVHD) prophylaxis, novel approaches to effective prevention of chronic GVHD (cGVHD) remain of high importance. In this prospective, multicenter, phase 2 trial, ruxolitinib, an oral inhibitor of Janus kinase (JAK) 1 and 2, was administered as maintenance therapy after reduced-intensity allogeneic hematopoietic cell transplantation (HCT). GVHD prophylaxis consisted of tacrolimus and methotrexate. Ruxolitinib began between day +30 to 100 and was administered continuously in 28-day cycles for up to 24 cycles. Seventy-eight participants were enrolled before HCT; 63 participants received the intervention. The median start date of ruxolitinib after HCT was day +45. The most common grade ≥3 adverse events were neutropenia, thrombocytopenia, and anemia. Seven participants experienced grade ≥3 infectious events. GVHD-free, relapse-free survival at 1 year after HCT, the primary end point, was 70%. Grade 3 to 4 acute GVHD at 6 months was 4.8%, and moderate-severe cGVHD at 2 years was 16%. cGVHD requiring systemic therapy was 9.5% at 1 year and 13% at 2 years. Overall survival and progression-free survival at 2 years were 76% and 68%, respectively. Prolonged administration of ruxolitinib following HCT is associated with low rates of clinically significant cGVHD. The incorporation of JAK inhibition into GVHD prevention approaches warrants further investigation. This trial was registered at www.clinicaltrials.gov as #NCT03286530.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA.
- Department of Data Science, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA.
- Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA.
- Department of Hematology-Oncology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN.
- Bone Marrow Transplantation and Leukemia Section, Division of Oncology, Washington University School of Medicine in Saint Louis, Saint Louis, MO.
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.
ORCID-Profile: Zachariah DeFilipp, Shilton E Dhaver, Bhagirathbhai Dholaria, Mark A Schroeder, Sameem Abedin, Richard A Newcomb, Yi-Bin Chen, Gabriela S Hobbs
Zitieren
APA
DeFilipp, Z., Kim, H. T., Knight, L. W., O'Connor, S. M., Dhaver, S. E., White, M., Dholaria, B., Schroeder, M. A., Vasu, S., Abedin, S., Chung, J., El-Jawahri, A., Frigault, M. J., McAfee, S., Newcomb, R. A., O'Donnell, P. V., Spitzer, T. R., Chen, Y. B., & Hobbs, G. S. (2025). Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT. Blood, 145(20), 2312-2316. https://doi.org/10.1182/blood.2024028005
Vancouver
DeFilipp Z, Kim HT, Knight LW, O'Connor SM, Dhaver SE, White M, et al. Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT. Blood. 2025;145(20):2312-2316. doi:10.1182/blood.2024028005
BibTeX
@article{DeFilipp2025,
author = {DeFilipp, Zachariah and Kim, Haesook T and Knight, Laura W and O'Connor, Suzanne M and Dhaver, Shilton E and White, Meghan and Dholaria, Bhagirathbhai and Schroeder, Mark A and Vasu, Sumithira and Abedin, Sameem and Chung, Jooho and El-Jawahri, Areej and Frigault, Matthew J and McAfee, Steven and Newcomb, Richard A and O'Donnell, Paul V and Spitzer, Thomas R and Chen, Yi-Bin and Hobbs, Gabriela S},
title = {Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT},
journal = {Blood},
year = {2025},
volume = {145},
number = {20},
pages = {2312--2316},
doi = {10.1182/blood.2024028005}
}
EUVIMED